Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
Japan’s ruling coalition partners are in the final stages of reaching an agreement on healthcare reforms that would revamp the Central Social Insurance Medical Council (Chuikyo) to strengthen the country’s drug discovery capabilities. The Liberal Democratic Party (LDP) and the…
To read the full story
Related Article
- LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
June 10, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- LDP, Ishin Call for Proper Valuation in CEA Scheme at Reform Talks
April 3, 2026
- Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026
REGULATORY
- Govt Eyes Honebuto Revisions on Biosimilars, MFN Policy
July 7, 2026
- LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
- Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
- MHLW Gives Kissei until July 21 to Report on Tavneos
July 3, 2026
- Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…